Breakthrough in Multiple Myeloma Treatment with Single-Dose CAR-T Therapy
TL;DR Summary
A study shows that a single infusion of CAR-T therapy cilta-cel can lead to at least five years of remission in about one-third of patients with relapsed or refractory multiple myeloma, suggesting potential curative outcomes for some patients.
Topics:business#cancer-treatment#car-t-therapy#cilta-cel#health#long-term-remission#multiple-myeloma
- Single-dose CAR-T therapy potentially curative in multiple myeloma Medical Xpress
- From No Hope to a Potential Cure for a Deadly Blood Cancer The New York Times
- Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting Yahoo Finance
- Israeli researchers help achieve breakthrough in myeloma treatment Ynetnews
- Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma The ASCO Post
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
93%
526 → 38 words
Want the full story? Read the original article
Read on Medical Xpress